SHANGHAI - AstraZeneca is investing $100 million to expand its current site in the Shanghai Zhangjiang Hi-Tech Park to strengthen its China headquarters and beef up marketing, R&D and academic training
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
